Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Rises By 27.1%

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 2,720,000 shares, an increase of 27.1% from the June 30th total of 2,140,000 shares. Based on an average daily trading volume, of 166,100 shares, the short-interest ratio is currently 16.4 days. Approximately 20.3% of the company’s shares are sold short.

Insider Transactions at INmune Bio

In related news, Director Scott Juda purchased 5,000 shares of INmune Bio stock in a transaction that occurred on Tuesday, June 25th. The shares were acquired at an average cost of $7.27 per share, for a total transaction of $36,350.00. Following the transaction, the director now directly owns 71,603 shares in the company, valued at $520,553.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 35.20% of the company’s stock.

Institutional Investors Weigh In On INmune Bio

Several institutional investors and hedge funds have recently bought and sold shares of INMB. Bank of New York Mellon Corp raised its holdings in shares of INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares in the last quarter. Westside Investment Management Inc. increased its position in INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after purchasing an additional 10,950 shares during the period. Fermata Advisors LLC raised its holdings in INmune Bio by 8.5% in the 2nd quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after purchasing an additional 2,689 shares in the last quarter. Finally, Financial Advocates Investment Management lifted its position in shares of INmune Bio by 8.6% in the 4th quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock worth $141,000 after purchasing an additional 990 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Trading Up 1.3 %

NASDAQ:INMB opened at $8.58 on Friday. INmune Bio has a 52 week low of $6.50 and a 52 week high of $14.74. The company has a fifty day moving average of $8.78 and a 200 day moving average of $10.57.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.61) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 86.16%.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.